TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36470985

Group type: EXPERIMENTAL
Intervention: Fat Grafting (FG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 15
Study: 33528537

Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU) dispatched (n=749)
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Conventional ambulance only (n=794)
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU) dispatched
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Conventional ambulance only
Number of subjects: 1543
Study: 32211417

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated abutment with soft tissue preservation surgery
Number of subjects: 103

Group type: COMPARATOR
Intervention: Titanium abutment with soft tissue reduction surgery (control)
Number of subjects: 103
Study: 35690093

Group type: EXPERIMENTAL
Intervention: 5% dextrose injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (0.9% sodium chloride) injection
Number of subjects: 40
Study: 36096948

Group type: EXPERIMENTAL
Intervention: Complex regional advance care planning (ACP) intervention
Number of subjects: 3840

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 3840
Study: 35918728

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 34444872

Group type: EXPERIMENTAL
Intervention: Aquatic resistance interval training plus nutritional intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nutritional intervention (Control)
Number of subjects: 34
Study: 32768682

Group type: EXPERIMENTAL
Intervention: Enhanced Stop Light Diet (eSLD) with behavioral counseling and increased physical activity delivered individually at home
Number of subjects: 128

Group type: COMPARATOR
Intervention: Enhanced Stop Light Diet (eSLD) with behavioral counseling and increased physical activity delivered to groups via video conferencing
Number of subjects: 128
Study: 36123185

Group type: EXPERIMENTAL
Intervention: Drilling guide group (digitally fabricated drilling guide using intraoral scan, CAD, and 3D printing)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Freehand group (screw channel preparation based on panoramic radiographs without a drilling guide)
Number of subjects: 24
Study: 35124916

Group type: EXPERIMENTAL
Intervention: Distance learning IMCI training
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard IMCI training (Control)
Number of subjects: 4
Study: 36195602

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectancy effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging
Number of subjects: 0
Study: 34045114

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion policy (packed cells when Hemoglobin < 8 g/dL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Liberal transfusion policy (packed cells when Hemoglobin < 10 g/dL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion policy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Liberal transfusion policy
Number of subjects: 80
Study: 33104004

Group type: EXPERIMENTAL
Intervention: Electronic Acupuncture Shoes (EAS)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham EAS plus NSAIDs (Control)
Number of subjects: 83
Study: 35938263

Group type: EXPERIMENTAL
Intervention: 8-week hatha yoga intervention
Number of subjects: 7
Study: 33547949

Group type: EXPERIMENTAL
Intervention: UTMD + XRT
Number of subjects: 24

Group type: COMPARATOR
Intervention: XRT
Number of subjects: 24
Study: 35101644

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 995
Study: 33887449

Group type: EXPERIMENTAL
Intervention: Visualization group (image-guided technique)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard group (standard approach)
Number of subjects: 80
Study: 35413602

Group type: EXPERIMENTAL
Intervention: Pequi oil nanoencapsulated gel (PeONC)
Number of subjects: 0
Study: 33814235

Group type: EXPERIMENTAL
Intervention: Men with overweight or obesity
Number of subjects: 2554

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 2554

Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 2554

Group type: EXPERIMENTAL
Intervention: Overweight subjects
Number of subjects: 2554

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 2554
Study: 35749267

Group type: EXPERIMENTAL
Intervention: MAX intervention (problem-solving therapy with energy conservation education)
Number of subjects: 41

Group type: COMPARATOR
Intervention: HE intervention (health education including diet, exercise, and energy conservation education)
Number of subjects: 41
Study: 35354828

Group type: EXPERIMENTAL
Intervention: Risk scoring system for progression to severe pneumonia
Number of subjects: 561
Study: 34719406

Group type: EXPERIMENTAL
Intervention: Family presence during the weaning process from mechanical ventilation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no family presence)
Number of subjects: 70
Study: 33415866

Group type: EXPERIMENTAL
Intervention: Moxibustion therapy (once daily for 14 days)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Moxibustion therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Basic treatment (western medicine)
Number of subjects: 95
Study: 34954870

Group type: EXPERIMENTAL
Intervention: Digital informed consent (DIC) using hyperrealistic simulation on a tablet device
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no hyperrealistic simulation)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DIC group (subgroup analysis for low education levels)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DIC group (subgroup analysis for higher education levels)
Number of subjects: 84
Study: 33185144

Group type: EXPERIMENTAL
Intervention: Hybrid Convergent
Number of subjects: 153

Group type: COMPARATOR
Intervention: CA
Number of subjects: 153
Study: 36167477

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% 30 mL on each side
Number of subjects: 69

Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 69
Study: 33393805

Group type: EXPERIMENTAL
Intervention: Strategic supports at encoding, monitoring, and cue detection (implementation intentions, visualization, content-free cuing, auditory alarm)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cue detection and combination conditions
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Supported PM accuracy in the laboratory
Number of subjects: 116

Group type: COMPARATOR
Intervention: Unsupported control condition
Number of subjects: 116

Group type: COMPARATOR
Intervention: Seronegative participants (unsupported control group)
Number of subjects: 116
Study: 36145227

Group type: EXPERIMENTAL
Intervention: Salt-reduced bread alone (Intervention A)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Salt-reduced bread with dietary counselling (Intervention B)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control (regular salt content bread)
Number of subjects: 309
Study: 34350865

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 47
Study: 33670720

Group type: EXPERIMENTAL
Intervention: Eggs enriched with ALA, DHA, RmA, and PunA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Eggs enriched with oleic acid (control group)
Number of subjects: 24
Study: 33243334

Group type: EXPERIMENTAL
Intervention: FIo₂ of 0.21 (normoxic)
Number of subjects: 16

Group type: COMPARATOR
Intervention: FIo₂ of 0.15 (hypoxic)
Number of subjects: 16
Study: 33593702

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI and diffusion-weighted imaging after two cycles of NAC
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Prediction model based on MRI parameters
Number of subjects: 87
Study: 33215768

Group type: EXPERIMENTAL
Intervention: Foam dressing
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 88
Study: 36207643

Group type: EXPERIMENTAL
Intervention: Propofol administered through a target-controlled infusion device programmed with the covariates model, plasma target concentrations between 2 and 5 μg.mL−1.
Number of subjects: 29
Study: 34533825

Group type: EXPERIMENTAL
Intervention: 20 opioid pills (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 opioid pills (Group 2)
Number of subjects: 60
Study: 32609075

Group type: EXPERIMENTAL
Intervention: Botrytis prunorum isolates
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Boscalid
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cyprodinil/fludioxonil mixture
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Fenhexamid
Number of subjects: 3
Study: 36055294

Group type: EXPERIMENTAL
Intervention: Community mobilisation intervention
Number of subjects: 38400

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 38400
Study: 33851991

Group type: EXPERIMENTAL
Intervention: Surgery with plate fixation (n = 38)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Functional bracing (n = 44)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Secondary surgery group (n = 14)
Number of subjects: 82
Study: 35642498

Group type: EXPERIMENTAL
Intervention: Bioactive glass granules
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard bone grafts (autologous and allogeneic)
Number of subjects: 49
Study: 33039944

Group type: COMPARATOR
Intervention: Ocrelizumab 600 mg administered over 3.5 hours (conventional duration)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600 mg administered over 2 hours (shorter duration)
Number of subjects: 745
Study: 612819042

Group type: EXPERIMENTAL
Intervention: Patient pain education programs (PEPs)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 54
Study: 33963479

Group type: EXPERIMENTAL
Intervention: β ‐glucan (200 mg daily)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 33675850

Group type: EXPERIMENTAL
Intervention: Methotrexate (25 mg weekly oral)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (1.5 g twice daily oral)
Number of subjects: 216
Study: 32169380

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Environmental exposure chamber (EEC)
Number of subjects: 24
Study: 35230140

Group type: EXPERIMENTAL
Intervention: Multimodal cocktail
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ropivacaine plus patient‐controlled analgesia
Number of subjects: 100
Study: 32050234

Group type: EXPERIMENTAL
Intervention: Small incision lenticule extraction (SMILE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femtosecond laser‐assisted laser in situ keratomileusis (FS‐LASIK)
Number of subjects: 60
Study: 36480788

Group type: EXPERIMENTAL
Intervention: No Pain III™ computer-controlled local anesthesia delivery (CCLAD) system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 30
Study: 32651955

Group type: EXPERIMENTAL
Intervention: PT20 (400, 800, 1600 or 3200 mg)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: PT20
Number of subjects: 153
Study: 32245696

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day)
Number of subjects: 353
Study: 32093617

Group type: EXPERIMENTAL
Intervention: Sumatriptan (4 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 34
Study: 32556659

Group type: EXPERIMENTAL
Intervention: SRP + nutraceutical agent (test group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: SRP alone (control group)
Number of subjects: 66
Study: 32351995

Group type: EXPERIMENTAL
Intervention: Dingji Fumai Decoction (DFD) combined with metoprolol
Number of subjects: 144

Group type: COMPARATOR
Intervention: Metoprolol combined with placebo (MET)
Number of subjects: 144
Study: 36081470

Group type: EXPERIMENTAL
Intervention: SAS video collage arm
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Attention placebo control video arm
Number of subjects: 10000

Group type: COMPARATOR
Intervention: No intervention arm
Number of subjects: 10000
Study: 32059691

Group type: EXPERIMENTAL
Intervention: CRT-lower limb (LL) plus PNF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CRT-lower limb (LL) and respiration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CRT-upper limb (UL) plus PNF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CRT-upper limb (UL) and respiration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 40
Study: 34459089

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention (CBT) with compassion-focused therapy methods, delivered in six sessions.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention (CBT)
Number of subjects: 22
Study: 34020614

Group type: EXPERIMENTAL
Intervention: Family Based Intervention (FBI) involving a multicomponent health-promotion intervention targeting children, families, and CCC, based on the Motivational Interviewing (MI) approach, focusing on dietary habits, physical activity, screen time, sleep duration, and psychological well-being.
Number of subjects: 810

Group type: COMPARATOR
Intervention: Control group participated in a unique workshop on general awareness of healthy lifestyles for families.
Number of subjects: 810
Study: 36203226

Group type: EXPERIMENTAL
Intervention: T1 C-based models
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: ADC-based models
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: T2 W-based models
Number of subjects: 136
Study: 33077017

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HYPER) infusion (0.1 ml/kg per min for 2 hours)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 0.9% isotonic saline (ISO) as control
Number of subjects: 49
Study: 35595850

Group type: EXPERIMENTAL
Intervention: Teleguided multidisciplinary intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care plus educational website access (Control)
Number of subjects: 58
Study: 33896823

Group type: EXPERIMENTAL
Intervention: miR‐142‐3p, miR‐146a‐5p, and miR‐151a‐5p in plasma of EC patients
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 3‐miRNA signature
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: miR‐151a‐5p in plasma exosomes
Number of subjects: 93
Study: 33523582

Group type: EXPERIMENTAL
Intervention: PICSI
Number of subjects: 45

Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 45
Study: 35412061

Group type: EXPERIMENTAL
Intervention: Portable ultrasound-guided REBOA
Number of subjects: 11

Group type: COMPARATOR
Intervention: Traditional manual extracorporeal compression
Number of subjects: 11
Study: 33964853

Group type: EXPERIMENTAL
Intervention: Wolfberry (15 g/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 32354795

Group type: EXPERIMENTAL
Intervention: CA19-9
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: SLX
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: LDH
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Tumor Size
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Mural Nodule Presence
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 283

Group type: COMPARATOR
Intervention: CA125
Number of subjects: 283
Study: 35404830

Group type: EXPERIMENTAL
Intervention: VR-enhanced Behavioral Activation (VR BA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Traditional Behavioral Activation (BA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 13
Study: 33450885

Group type: EXPERIMENTAL
Intervention: Probiotic HN001 (n = 172)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo (n = 176)
Number of subjects: 348
Study: 32862743

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 34789846

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for alcohol use in African Americans (AA)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for alcohol use in European Americans (EA)
Number of subjects: 463
Study: 36096706

Group type: EXPERIMENTAL
Intervention: CAS risk score group
Number of subjects: 5206

Group type: COMPARATOR
Intervention: CHA2DS2-VASc risk score group
Number of subjects: 5206
Study: 34056740

Group type: EXPERIMENTAL
Intervention: Urate levels (genetic variants underlying urate levels)
Number of subjects: 0
Study: 35086677

Group type: EXPERIMENTAL
Intervention: MIKT
Number of subjects: 148

Group type: COMPARATOR
Intervention: CKT
Number of subjects: 148
Study: 34657274

Group type: EXPERIMENTAL
Intervention: AVT02
Number of subjects: 413

Group type: COMPARATOR
Intervention: Originator adalimumab
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: AVT02 and Originator adalimumab
Number of subjects: 413
Study: 35193729

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cariprazine 6 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32402261

Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 151
Study: 36216004

Group type: EXPERIMENTAL
Intervention: Low sodium diet of less than 1500 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care according to local guidelines
Number of subjects: 0
Study: 34112174

Group type: EXPERIMENTAL
Intervention: Person-centred transition programme
Number of subjects: 26

Group type: COMPARATOR
Intervention: Support to parents
Number of subjects: 26
Study: 32379657

Group type: EXPERIMENTAL
Intervention: Laughter programme with entrainment music
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 35680626

Group type: EXPERIMENTAL
Intervention: IAC regimen (idarubicin, cytarabine, and cyclophosphamide)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control regimen (selected by doctors)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IAC regimen
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-hematopoietic stem cell transplantation group
Number of subjects: 42
Study: 33932589

Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg, intravenously, Q 12 h) for the first 5 postoperative days
Number of subjects: 134

Group type: COMPARATOR
Intervention: On-demand opioid analgesics (pethidine or morphine) postoperatively
Number of subjects: 134
Study: 35829974

Group type: EXPERIMENTAL
Intervention: Delicate pulsed light (DPL) combined with low-dose oral isotretinoin (10–20 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isotretinoin monotherapy
Number of subjects: 36
Study: 33888069

Group type: EXPERIMENTAL
Intervention: Vocal cord radiotherapy (VC‐RT)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Complete laryngeal radiotherapy (CL‐RT)
Number of subjects: 155
Study: 35040001

Group type: EXPERIMENTAL
Intervention: Parent‐implemented Early Start Denver Model (P‐ESDM) with Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Parent‐implemented Early Start Denver Model (P‐ESDM) without Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 63
Study: 35362185

Group type: EXPERIMENTAL
Intervention: Reproductive coercion experience among female participants
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Care seeking for counselling and healthcare among female participants who experienced reproductive coercion
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Recent use of reproductive coercion among male participants
Number of subjects: 2291
Study: 34379891

Group type: EXPERIMENTAL
Intervention: NIV‐NAVA
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 23

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 23
Study: 35379633

Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreaticoduodenectomy (LPD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Open pancreaticoduodenectomy (OPD)
Number of subjects: 200
Study: 33742786

Group type: EXPERIMENTAL
Intervention: HBM9161 340 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HBM9161 510 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HBM9161 680 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HBM9161
Number of subjects: 24
Study: 32799925

Group type: EXPERIMENTAL
Intervention: PRIMROSE intervention
Number of subjects: 30
Study: 35034311

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim-cbqv
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pegfilgrastim
Number of subjects: 0
Study: 33567406

Group type: EXPERIMENTAL
Intervention: Dual-task head rotations on foam condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dual-task head rotations on firm surface
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual field flow on firm surface
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Head rotations on foam surface
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 20
Study: 32521553

Group type: EXPERIMENTAL
Intervention: 26-item German IQCODE version (telephone interview)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10-item short telephone version of the IQCODE
Number of subjects: 60
Study: 35783528

Group type: EXPERIMENTAL
Intervention: Xinjia Xuanbai Chengqi granules (XJXBCQ) combined with conventional treatment (budesonide suspension)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Xinjia Xuanbai Chengqi granules (XJXBCQ) and budesonide suspension (full dosage)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (budesonide suspension and placebo)
Number of subjects: 330